Atai posts $26M loss, but progresses on psychedelic clinical trials
The clinical-stage biopharmaceutical company said it has enough cash to reach the milestones it laid out for 2025.
The post Atai posts $26M loss, but progresses on psychedelic clinical trials appeared first on Green Market Report.
